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Abstract
Phthalates are a group of chemical compounds used as plasticizers in the manufacture of plastic materials. They can be present in
many commonly used products. There seems to be a relationship between exposure to phthalates and the occurrence of metabolic
dysfunctions, such as a decrease in glucose tolerance, oxidative stress, loss of beta cells, and a decrease in insulin synthesis. As
beta cells play a key role in the onset of type 1 diabetes mellitus (T1DM), we sought to investigate the relationship between
exposure to phthalates and the diagnosis of T1DM in prepubertal children. Design concentrations of phthalate metabolites were
compared in the urine of a population of prepubertal children with new-onset diabetes, patients with T1DM diagnosed more than
6 months previously, and healthy control children. Although the concentrations of DBP and DiBP metabolites were statistically
identical in the new-onset diabetes, diabetes, and control groups, there was a clear trend for higher levels of DiBP metabolites in
the children with new-onset diabetes. In our sample, there was a trend for higher levels of DiBPmetabolites in children with new-
onset diabetes.
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Abbreviations
BMI Body mass index
DEHP Di(2-ethylhexyl)phthalate
DBP Dibutyl phthalate
DIBP Diisobutyl phthalate
LOD Limit of detection
MBP Monobutyl phthalate
MiBP Mono-isobutyl phthalate
T1DM Type 1 diabetes mellitus
Introduction
Phthalates are a group of chemical compounds used in the
manufacture of plastic materials, such as PVC (Wittassek
et al. 2007). They are frequently used as plasticizers (Koch
and Calafat 2009). Since phthalates are not chemically bound
to the plastic structure, these compounds may be released to
the air and other media with which they are in contact. Their
main route of entry into the body is through ingestion of con-
taminated food (Dong et al. 2017). Because plastic materials
containing phthalates as plasticizers are used on a large scale,
phthalates can be present in toys, building materials, food
packaging, and various other commonly used products
(Fourth Report 2009). In recent years, phthalate production
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has increased significantly (Baillie-Hamilton 2002), and their
importance in public health is reflected, for example, by the
fact that the majority of the European population excrete
phthalate metabolites in their urine samples (Schwedler et al.
2017).
Among phthalates, the compound dibutyl phthalate (DBP)
stands out as one of the most abundant components of some
plastics (Wittassek et al. 2007).
DBP is not chemically bound to PVC and may, over time,
contaminate other materials (Moreira et al. 2013).
Phthalates have the capacity to function as endocrine
disruptors. They seem to interfere with a multitude of mecha-
nisms, influencing the hormonal status (Sun et al. 2017).
Phthalates are able to disrupt the hypothalamic-pituitary-
thyroid axis (HPTA) (Sun et al. 2017). They seem to play a
major role in testicular dysgenesis syndrome, a syndromic
complex accounting for a number of genito-reproductive dis-
orders (Skakkebaek et al. 2003).
Phthalates may alter glucose metabolism and adipogenesis
(Grun and Blumberg 2007; Casals-Casas et al. 2008;
Desvergne et al. 2009). Elevated levels of phthalates have been
associated with an increased BMI and waist circumference in
adults and children (Stahlhut et al. 2007; Hatch et al. 2008).
Perinatal exposure to DEHP in rats results in important
alterations in glucose homeostasis, which are gender- and
age-dependent (Lin et al. 2011).
The onset of type 2 diabetes mellitus and metabolic syn-
drome after exposure to phthalates seems to have insulin resis-
tance as its underlyingmechanism (Song et al. 2016), and some
studies have demonstrated that alterations in oxidative stress,
induced by phthalates, are a causative factor (Kim et al. 2013).
Exposure to phthalates leads to a reduction in the pancreatic
insulin content, a loss of beta cells, and an abnormal ultrastruc-
tural pattern of these cells (Lin et al. 2011). Human and rat
studies have shown that the presence of DEHP is associated
with DNA damage (Caldwell 2012). This change may induce
an alteration in insulin synthesis. Many studies have been con-
ducted on DEHP, but much less investigation has been carried
out on other phthalates, such as DBP and DiBP.
Given that beta cells play a key role in the onset of type 1
diabetes mellitus (T1DM) and that many of the changes de-
scribed above cause a decrease in the number of these cells, a
relationship between the exposure to DBP and DiBP and the
diagnosis of T1DMwas investigated in a prepubertal children
group in this study.
Materials and methods
Participants
From a total of 302 T1DM patients followed up at the pediat-
ric endocrinology clinic, 20 patients (12 males and 8 females)
were randomly selected based on the assumption that they
were prepubertal. These patients were aged 6 to 10 years,
had a body mass index (BMI) below the 85th percentile, and
were diagnosed with T1DM more than 6 months previously;
they had no microvascular complications and no other dis-
eases, and they did not use any associated medications. In
the same period of time (2012–2014), all children with an
initial diagnosis of diabetes (< 6 months after diagnosis) who
visited the Endocrinology Clinic of the São JoãoHospital (n =
8) were included. São João is a university general hospital
focused on providing the best health care, with high levels
of competence and excellence, and encouraging training and
research.
The control group included healthy children followed up at
the pediatric surgery unit (n = 10) and hospitalized for minor
planned surgical procedures.
All the diabetic children were treated with glargine and
rapid-acting analogues (lispro, aspart, or glulisine) through
multiple daily injections, according to the ISPAD
(International Society of Pediatric and Adolescent Diabetes)
guidelines (Danne et al. 2014).
All urine samples were collected in glass containers so that
the contamination factor was reduced.
The project was approved by the Institutional Ethics
Committee, and all patients’ parents/guardians signed an in-
formed consent form prior to the commencement of the study.
Chemical analysis
Urine samples were collected on the same day and stored at
− 20 °C until analysis. The samples were analyzed for
phthalates and metabolites via solid-phase extraction-gas
chromatography/mass spectrometry (SPE-GC/MS) after
enzymatic hydrolysis with beta-glucuronidase overnight
at 37 °C (from E. coli, without arylsulfatase activity); the
internal standard DEHP-3,4,5,6-d4 was also added.
Elution was performed with ethyl acetate, and then the
samples were dried under a gentle stream of N2 and
redissolved in 100 μL of the derivatization reagent (N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) + 1%
trimethylchlorosilane (TMCS)). This mixture was placed
in a water bath at 80 °C for 30 min. The final extract was
transferred to a glass insert (in a GC vial) and analyzed using
the GC-MS system. Chromatographic analyses were carried
out in a TRACE GC Ultra gas chromatograph with Polaris Q
coupled to an ion trap mass spectrometer (Thermo Fisher
Scientific) operated in electron impact ionization (EI) mode
at 70 eV and controlled by Xcalibur 1.3. The helium carrier
gas (Linde Sógas, purity ≥ 99.999%) was maintained at a con-
stant flow of 1 mL/min. Injections (2 μL) were carried out in
splitless mode. A Phenomenex ZB-XLB column (30 m ×
0.25 mm I.D., 0.25-μm film thickness) was used. The GC
oven temperature was programmed from an initial
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temperature of 90 °C (1 min hold), ramped up at 15 °C/min to
250 °C (1 min hold), increased to 255 °C at 20 °C/min (5 min
hold), and finally increased to 270 °C at 10 °C/min (1 min
hold). This program resulted in a total run time of 23.42 min.
The other optimized parameters included a transfer line tem-
perature of 270 °C and an ion source temperature of 250 °C.
The compounds were quantified with selected ion monitoring
(SIM). Identification was confirmed by the retention times and
ion ratios.
The method detection limits (MDLs) in the urine were
0.0011 and 0.00018 mcg/L for mono-isobutyl phthalate
(MiBP) and monobutyl phthalate (MBP), respectively.
Statistical methods
Some of the evaluated children presented with values lower
than the limit of detection (LOD). Therefore, the groups (dia-
betes, new diabetes and control) were compared using
Fisher’s exact test in terms of the percentage of children who
had measurable levels of phthalate metabolites in their urine.
The Kruskal-Wallis test was then used to compare phthal-
ate levels among the groups in only those cases in which these
levels were measurable.
A significance level of 0.05 was used for all tests.
Results
The children were divided into three groups as follows: with-
out diabetes (controls); with T1DM for more than 6 months
(diabetes); and new-onset diabetes (new diabetes).
The characteristics of the patients are described in Table 1.
Some of the children evaluated had phthalate concentra-
tions lower than the LOD, and others had phthalate concen-
trations lower than the LOQ. Neither of these groups were
taken into account. No statistically significant differences
were found among the groups in the percentage of cases with
measurable levels of phthalates (Table 2).
MiBP is a urinary metabolite of the parental chemical
diisobutyl phthalate (DiBP), and MBP is a di-n-butyl phthal-
ate (DBP) metabolite.
Considering only the children who had detectable phthalate
concentrations in the urine, there were no statistically signifi-
cant differences in the DBP and DiBP urine metabolites
among the groups (Table 3). Nevertheless, there was a clear
trend towards higher median values in the children with inau-
gural diabetes.
Discussion
For many reasons, children are more susceptible to the harm-
ful effects of endocrine disruptors. A child’s metabolic re-
sponse to the presence of these substances is different from
that of adults (Ginsberg et al. 2004; Faustman et al. 2000).
Children have higher metabolic needs, with a greater need
for food and water intake per body weight (Moya et al.
2004). Children are also often more exposed to phtalate-
containing materials because of physiological and behavioral
factors. They may have behaviors that pose a greater risk of
contact with contaminants, such as placing objects in their
mouths and crawling (Moya et al. 2004), especially younger
children.
Diisobutyl phthalate (DIBP) is a colorless, transparent, oily
liquid used as an alternative to DBP (dibutyl phthalate). It is
used in nitrocellulose and alkyd resin paints. Both DIBP and
DBP are plasticizers. Phthalates are not tightly bound to the
plastic; therefore, they are easily released into the environ-
ment, accumulating in the dust in a house (Ginsberg et al.
2016). Both plasticizers are found to be major contributors
to phthalate exposure through ingestion (Weldingh et al.
2017).
Exposure to these substances has been decreasing in the
past few years, likely due to the legislation regarding their
Table 1 Characteristics of the
evaluated patients by groups Controls
(n = 10)
median (min–max)
Diabetes
(n = 20)
median (min–max)
New diabetes
(n = 8)
median (min–max)
Age at diagnosis (years) – 3.2 (0.9–9.1) 8.9 (2.3–9.7)
Current age (years) 5.3 (3.1–8.6) 7.3 (3.5–11.3) 9.0 (2.2–9.7)
Illness duration (years) – 2.6 (0.3–7.2) –
BMI 17.0 (15.4–20.8) 17.0 (15.8–22.1) 16 (14.5–19.2)
HbA1c (%) – 8.3 (6.6–10.2) 9.4 (8.2–10.6)
Table 2 Statistics of the cases who had measurable levels of phthalates
Controls
(n = 10)
n (%)
Diabetes
(n = 20)
n (%)
New diabetes
(n = 8)
n (%)
p
MIBP 9 (90) 15 (75) 7 (88) 0.640
MBP 2 (20) 3 (15) 3 (38) 0.435
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use. However, despite the existence of European or American
laws, there are other countries that do not follow the same
rules and still use plastics with a higher percentage of
phthalates, including in toys.
In Portugal, the presence of some phthalates in tap water, as
well as in several samples of bottled water (mostly in plastic
bottles), was investigated (Santana et al. 2014). Three
phthalates (dibutyl (DnBP), diisobutyl (DIBP) and DEHP)
were found (Santana et al. 2014). The concentration of
DEHP was approximately five times higher in the water in
plastic bottles than in the water in glass bottles (Santana et al.
2014). In tap water, only DIBP and DEHP were found
(Santana et al. 2014). All samples had phthalate concentra-
tions below 6 μg/l, which is the maximum allowed concen-
tration in water established by the US Environmental
Protection Agency (Santana et al. 2014).
Samples from children in our study contained MiBP, a
DiBP metabolite, with a much smaller percentage of samples
containing DBP metabolites.
Phthalates are substances that function as endocrine
disruptors. They may show insulin resistance-inducing effects
and aggravate metabolic syndrome (Grun and Blumberg
2007). There is also evidence of some direct effects on beta
cells, with a consequent decrease in their insulin secretory
potential (Tordjman et al. 2002).
In the past few decades, the incidence of diabetes has in-
creased markedly worldwide (Weldingh et al. 2017). This in-
crease coincides with amarked increase in exposure to a number
of synthetic chemicals, including several substances known to
have the capacity for endocrine disruption (WHO 2013).
These facts led to the concept of a possible relationship
between the exposure to endocrine disruptors and the increase
in diabetes mellitus (Neel and Sargis 2011).
T1DM is an autoimmune disease characterized by an ex-
tensive loss of pancreatic beta cells and consequent insulin
deficiency and hyperglycaemia (Mathis et al. 2001). The un-
derlying mechanism is a process of cell death, which is in-
duced by cytokines (Pirot et al. 2008).
Although several studies have sought to establish a relation-
ship between phthalate exposure and the onset of type 2 diabe-
tes, the relationship between these substances and T1DM has
been investigated less frequently (Weldingh et al. 2017).
Lin et al. have shown that in rats, exposure to DEHP during
pregnancy led to changes in glucose metabolism in the
offspring (Lin et al. 2011). Additionally, direct exposure of
pancreatic cells to DEHP caused apoptosis and altered insulin
secretion (Sun et al. 2015).
The development of pancreatic autoimmunity precedes the
destruction of beta cells and the diagnosis of T1DM
(Eisenbarth 1986). Studies have shown a possible relationship
between the presence of DBP and the development of immu-
nity (Lourenço et al. 2015). Phthalates, namely, DBP, seem to
be able to induce thyroiditis, also an autoimmune disease (Wu
et al. 2017).
We evaluated the possibility of the same phenomenon with
regard to beta cells, with possible autoimmune mechanisms
triggered by the exposure to these endocrine disruptors.
Although the median values in the diabetes and new dia-
betes groups of children were higher than those in the controls,
there were no statistically significant differences among the
three groups. However, there was a clear trend for the children
with new-onset diabetes to have higher urinary concentrations
of phthalate metabolites. Certainly, one of the limitations of
our investigation is a small sample size, which may have con-
tributed to the lack of statistical significance.
One factor to be taken into account is that all overweight
and obese children were excluded because obesity and over-
weight could be a confounding factor in this analysis.
Conclusion
No statistically significant differences were found in the con-
centrations of urinary metabolites of DiBP and DBP among
newly diagnosed diabetic children, children with established
type 1 diabetes and healthy controls. However, children re-
cently diagnosed with diabetes showed a tendency to have
higher DiBP metabolite concentrations. Considering recent
data on these pollutants, it is imperative to conduct clinical
studies with larger population samples.
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